Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bolt Biotherapeutics (BOLT) EBIT (2020 - 2025)

Bolt Biotherapeutics' EBIT history spans 6 years, with the latest figure at -$7.7 million for Q3 2025.

  • For Q3 2025, EBIT rose 53.15% year-over-year to -$7.7 million; the TTM value through Sep 2025 reached -$45.9 million, up 39.47%, while the annual FY2024 figure was -$73.0 million, 4.13% up from the prior year.
  • EBIT for Q3 2025 was -$7.7 million at Bolt Biotherapeutics, up from -$9.2 million in the prior quarter.
  • Across five years, EBIT topped out at -$7.7 million in Q3 2025 and bottomed at -$27.1 million in Q4 2021.
  • The 5-year median for EBIT is -$19.8 million (2023), against an average of -$19.0 million.
  • The largest annual shift saw EBIT tumbled 113.87% in 2021 before it surged 59.24% in 2025.
  • A 5-year view of EBIT shows it stood at -$27.1 million in 2021, then increased by 22.29% to -$21.0 million in 2022, then rose by 6.06% to -$19.8 million in 2023, then rose by 14.42% to -$16.9 million in 2024, then soared by 54.46% to -$7.7 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's EBIT are -$7.7 million (Q3 2025), -$9.2 million (Q2 2025), and -$12.1 million (Q1 2025).